Enanta Pharmaceuticals, Inc. (15)
Browse by Contract Category
Contracts
-
Open Market Sale AgreementSM dated August 26, 2022, by and between Enanta Pharmaceuticals, Inc. and Jefferies LLC
(Filed With SEC on August 26, 2022)
-
First Amendment to Lease Agreement made as of May 12, 2022 by and between ARE-MA Region No. 75, LLC and the Company
(Filed With SEC on May 17, 2022)
-
Form of Consulting Agreement (Amended and Restated), Nathalie Adda
(Filed With SEC on May 9, 2022)
-
Second Amendment to Lease made as of May 12, 2022 by and between ARE-500 Arsenal Street, LLC and the Company
(Filed With SEC on May 17, 2022)
-
Lease Agreement made as of May 12, 2022 by and between ARE-MA Region No. 75, LLC and the Company
(Filed With SEC on May 17, 2022)
-
2019 Equity Incentive Plan (As amended through March 3, 2022)
(Filed With SEC on March 8, 2022)
-
Consulting Agreement with Nathalie Adda
(Filed With SEC on November 24, 2021)
-
2019 Equity Incentive Plan (As amended March 2021)
(Filed With SEC on March 5, 2021)
-
Form of Notice of Restricted Stock Unit Award under 2019 Equity Incentive Plan
(Filed With SEC on November 25, 2020)
-
Description of securities
(Filed With SEC on November 27, 2019)
-
Form of Notice of Grant of Non-Statutory Stock Option under 2019 Equity Incentive Plan
(Filed With SEC on May 10, 2019)
-
Form of Notice of Grant of Non-Statutory Stock Option for Directors under 2019 Equity Incentive Plan
(Filed With SEC on May 10, 2019)
-
Form of Relative Total Stockholder Return Unit Certificate under 2019 Equity Incentive Plan
(Filed With SEC on May 10, 2019)
-
Form of Performance Share Unit Certificate under 2019 Equity Incentive Plan
(Filed With SEC on May 10, 2019)
-
2019 Equity Incentive Plan
(Filed With SEC on March 7, 2019)